Epigenetic markers and related methods and means for the detection and management of certain cancers
The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection-from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women. The present invention further relates to nucleic acids comprising certain sequences that may be detected during the method, or nucleic acids (such as probes and/or primers) that are useful to detect such sequences, as wells as compositions, kits, computer program products and other aspects that are useful for or related to the practice or application of such methods.
1. A method of determining the presence of a cancer in a human individual, said method comprising:
providing a serum or plasma sample from said human individual, said sample comprising cell-free DNA;
determining, in at least one molecule of said cell-free DNA, the methylation status at 16 CpGs located at positions 28, 31, 33, 45, 52, 58, 60, 62, 69, 104, 107, 110, 116, 121, 124 and 126 within the nucleotide sequence of SEQ ID NO: 2 or a 100% complementary sequence to said nucleotide sequence;
determining the presence of cancer in said human individual when at least one molecule of said cell-free DNA is methylated at each of said 16 CpGs; and
treating the cancer in said human individual by (i) administering a chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, liposomal doxorubicin, gemcitabine, trabectedin, etoposide, cyclophosphamide, an angiogenesis inhibitor and a PARP inhibitor, or (ii) by performing tumor de-baulking surgery;
wherein (a) when the human individual is a woman the cancer is selected from the group consisting of: breast cancer, lung squamous cell carcinoma, colon cancer, pancreatic cancer, uterine (endometrial) cancer, and ovarian cancer; or (b) when the human individual is a man the cancer is selected from the group consisting of: lung squamous cell carcinoma, colon cancer, pancreatic cancer and prostate cancer.
2. The method of claim 1 , further comprising determining the methylation status at CpGs located in at least one nucleotide sequence selected from SEQ ID NOs: 1, 3, 4, and a 100% complementary sequence of said nucleotide sequence(s).
3. The method of claim 1 , further comprising the step of treating said cell-free DNA with an agent that differentially modifies said cell-free DNA based on the methylation status of the CpGs.
4. The method of claim 3 , wherein said agent is bisulfite.
5. The method of claim 1 , wherein the methylation status of said CpGs is determined in multiple molecules of said cell-free DNA.
6. The method of claim 5 , wherein a fraction or ratio of, or an absolute number of, cell-free DNA molecules in said sample having said methylated CpGs located within said nucleotide sequence, and/or having a pattern of methylation for the nucleotide sequence SEQ ID NO: 64, is estimated.
7. The method of claim 1 , further comprising using a primer pair for amplifying the nucleic acid sequence consisting of SEQ ID NO 64 or a 100% complementary sequence to said nucleotide sequence.
8. The method of claim 1 , wherein treating the cancer in said human individual comprises tumor de-baulking surgery.
9. The method of claim 1 , wherein the human individual is a woman and the cancer is selected from the group consisting of: breast cancer, uterine (endometrial) cancer, and ovarian cancer.
10. The method of claim 9 , wherein the cancer is ovarian cancer.
11. A method of treating cancer in a human individual previously treated with carboplatin comprising: administering a chemotherapeutic agent to said human individual previously treated with carboplatin within about 3 months of said human individual having been determined to have a reduced response to a carboplatin therapy by a method comprising:
providing a serum or plasma sample from said human individual, said sample comprising cell-free DNA;
determining, in at least one molecule of said cell-free DNA, the methylation status at 16 CpGs located at positions 28, 31, 33, 45, 52, 58, 60, 62, 69, 104, 107, 110, 116, 121, 124 and 126 within the nucleotide sequence of SEQ ID NO: 2 or a 100% complementary sequence to said nucleotide sequence;
determining that said human individual will have a reduced response to carboplatin therapy when at least one molecule of said cell-free DNA is methylated at each of the 16 CpGs;
wherein: (a) when the human individual is a woman the cancer is selected from the group consisting of: breast cancer, lung squamous cell carcinoma, colon cancer, pancreatic cancer, uterine (endometrial) cancer, and ovarian cancer; or (b) when the human individual is a man the cancer is selected from the group consisting of: lung squamous cell carcinoma, colon cancer, pancreatic cancer and prostate cancer; and
wherein the chemotherapeutic agent is selected from the group consisting of: paclitaxel, docetaxel, cisplatin, liposomal doxorubicin, gemcitabine, trabectedin, etoposide, cyclophosphamide, an angiogenesis inhibitor and a PARP inhibitor.
12. The method of claim 11 , further comprising the step of treating said cell-free DNA with an agent that differentially modifies said cell-free DNA based on the methylation status of the CpGs.
13. The method of claim 12 , wherein said agent is bisulfite.
14. The method of claim 11 , wherein the methylation status of said CpGs is determined in multiple molecules of said cell-free DNA.
15. The method of claim 14 , wherein a fraction or ratio of, or an absolute number of, cell-free DNA molecules in said sample having said methylated CpGs located within said nucleotide sequence, and/or having a pattern of methylation for the nucleotide sequence SEQ ID NO: 64, is estimated.
16. The method of claim 11 , wherein the carboplatin is carboplatin-based neoadjuvant chemotherapy.
17. The method of claim 11 , wherein the human individual is a woman and the cancer is selected from the group consisting of: breast cancer, uterine (endometrial) cancer, and ovarian cancer.
18. The method of claim 17 , wherein the cancer is ovarian cancer.